Market Place
Sourcing Support
Sciwind BiosciencesPresents GLP-2 Research At UEG Week 2024
07 Oct 2024 //
PR NEWSWIRE
Sciwind Biosciences Announces Oral Presentations at EASD 2024
05 Sep 2024 //
PR NEWSWIRE
Sciwind to Highlight Positive Results for Ecnoglutide and Amylin Analogs
21 Jun 2024 //
PR NEWSWIRE
Sciwind Bio Announces Positive Results from Phase 1 Clinical Trial of XW004
23 Jan 2024 //
PR NEWSWIRE
Sciwind posts pivotal data on Chinese GLP-1 rival to Novo, Lilly
03 Jan 2024 //
FIERCE BIOTECH
Sciwind Announces Publication of Phase 1 Clinical Trial Results of Ecnoglutide
11 Jul 2023 //
PR NEWSWIRE
Sciwind Announces Initiation of Patient Dosing in PIII Trials of Ecnoglutide
30 Jan 2023 //
PR NEWSWIRE
Sciwind Announces Positive Results from Ongoing Phase 2b Trial of XW003
27 Oct 2022 //
PRNEWSWIRE
Sciwind commences subject dosing in Phase I trial of oral drug for obesity
10 Oct 2022 //
CLINICALTRIALSARENA
Sciwind Announces Initiation of Dosing in Phase 1 Trial Evaluating XW014
09 Oct 2022 //
PRNEWSWIRE
Sciwind Biosciences Reports Positive Interim Results from PIc/IIa Trial of XW003
08 Aug 2022 //
PRNEWSWIRE
Sciwind Biosciences Announces Positive Topline Results from PII Trial of XW003
02 Aug 2022 //
PRNEWSWIRE
Sciwind Bio to present Data from its GLP-1 and GIP Receptor Agonist Programs
07 Jun 2022 //
PRNEWSWIRE
Sciwind starts subject dosing with Ecnoglutide’s oral form in Phase I trial
14 Apr 2022 //
CLINICALTRIALSARENA
Sciwind Bio Initiates Dosing in Phase 1 Trial Evaluating XW004
13 Apr 2022 //
PRNEWSWIRE
Sciwind Bio Initiates Dosing in Phase 2b Trial Evaluating XW003 for Obesity
17 Jan 2022 //
PRNEWSWIRE
Sciwind Completes Enrollment in Phase 2 Trial of XW003 in Type 2 Diabetes
09 Dec 2021 //
PRNEWSWIRE
Sciwind picks up $70M & seasoned execs to challenge NovoNordisk`s obesity drug
12 Oct 2021 //
ENDPTS
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.